CJC-1295 / Ipamorelin Blend
Dual-Receptor GH Stimulation for Pulsatile Growth Hormone Research
CJC-1295 / Ipamorelin Blend — Synergistic GH Secretagogue Combination
Last reviewed: August 2026
The CJC-1295/Ipamorelin blend combines two growth hormone-stimulating peptides that work through different receptors, producing synergistic GH release that closely mimics the body's natural pulsatile GH secretion.
CJC-1295 tells the pituitary to release GH through the GHRH receptor pathway, while Ipamorelin does the same through the ghrelin receptor (GHSR-1a). Using both together produces significantly more GH release than either peptide alone, without cortisol or prolactin elevation.
Growth hormone declines with age, contributing to reduced muscle mass, increased fat, and slower recovery. The CJC-1295/Ipamorelin combination restores youthful GH pulsatility without exogenous GH administration, preserving natural feedback mechanisms.
The CJC-1295/Ipamorelin blend is the gold standard GH secretagogue combination — synergistic dual-receptor activation, pulsatile GH release, and selective action without cortisol or prolactin elevation.
What is CJC-1295 / Ipamorelin Blend?
The CJC-1295 / Ipamorelin blend combines two complementary growth hormone secretagogues in a single formulation. CJC-1295 (a GHRH analogue) stimulates the pituitary to release GH through the GHRH receptor, while Ipamorelin (a ghrelin mimetic) activates GH release through the GHSR-1a receptor. Together, they produce synergistic, pulsatile GH release that closely mimics the body's natural GH secretion pattern.
- The CJC-1295/Ipamorelin blend combines a GHRH analog (CJC-1295 without DAC, half-life ~30 min) with a GHRP/ghrelin mimetic (Ipamorelin, half-life ~2 hours) to achieve synergistic GH pulse amplification.
- CJC-1295 (without DAC) increases the amplitude of GH pulses by stimulating GHRH receptors on pituitary somatotrophs; Ipamorelin increases GH pulse frequency by activating GHS-R1a (ghrelin receptor).
- The two mechanisms are complementary: GHRH analogs and GHRPs act on different receptors and through different second messenger pathways (cAMP/PKA for GHRH; IP3/PKC for ghrelin receptor), producing 3–5× greater GH release when combined vs either alone.
- Ipamorelin's high GHS-R1a selectivity means the blend avoids the cortisol and prolactin elevation associated with less selective GHRPs (GHRP-6, GHRP-2), making it a cleaner tool for GH axis research.
- Supplied as a pre-mixed lyophilized powder for research convenience; the blend does not contain CJC-1295 with DAC (Drug Affinity Complex), preserving pulsatile GH release rather than producing sustained GH elevation.
Molecular Composition
The blend contains equal parts CJC-1295 (a 30-amino-acid GHRH analogue with DAC technology for extended half-life) and Ipamorelin (a 5-amino-acid selective GHSR-1a agonist). The 1:1 ratio is designed to maximize synergistic GH release through complementary receptor pathways.
How Does It Work?
The CJC-1295/Ipamorelin blend produces synergistic GH release by simultaneously activating GHRH receptors and ghrelin receptors, generating pulses far greater than either peptide alone.
CJC-1295 activates GHRH receptors on somatotroph cells in the anterior pituitary, stimulating GH synthesis and release. Ipamorelin simultaneously activates GHSR-1a (ghrelin receptor) on the same cells, providing a complementary and synergistic signal. The combination produces GH release significantly greater than either peptide alone, while preserving the natural pulsatile pattern.
Key Research Pathways
Dual-Receptor GH Stimulation
CJC-1295 activates GHRH receptors while Ipamorelin activates GHSR-1a receptors, producing synergistic GH release significantly greater than either peptide alone.
Pulsatile GH Secretion Pattern
The combination preserves the natural pulsatile pattern of GH release, maintaining GH receptor sensitivity and avoiding tachyphylaxis.
Selective GH Release (No Cortisol/Prolactin)
Unlike older GH secretagogues, Ipamorelin does not stimulate cortisol or prolactin release, making the blend highly selective for GH secretion.
Key Findings from the Literature
- Synergistic dual-receptor GH stimulation (GHRH + GHSR-1a pathways)
- CJC-1295 produces sustained GH elevation for up to 6 days after a single injection (JCEM, 2006)
- Ipamorelin is selective for GH release — does not stimulate cortisol or prolactin
- Preserves natural pulsatile GH secretion pattern, maintaining receptor sensitivity
- Most studied GH secretagogue combination protocol in research literature
Evidence by Claimed Outcome
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Important Research Context
Research References
Peer-reviewed literature supporting the research profile of CJC-1295 / Ipamorelin Blend
The following peer-reviewed studies form the primary evidence base for CJC-1295 / Ipamorelin Blend's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006.PMID: 16352683
CJC-1295 component: sustained GH and IGF-1 elevation for up to 6 days after single injection.
- 2.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.PMID: 9849822
Ipamorelin component: selective GH release without cortisol or prolactin elevation.
- 3.
Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism. 1998.PMID: 9467542
GHS receptor agonism (shared with ipamorelin) increases fat-free mass and energy expenditure.
CJC-1295 / Ipamorelin Blend
Blends Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
10mg $55.99 → $44.79 with code HEALTH (20% off; price read 23 Sept 2026)
- 1 certificate verified at the lab10mg$69.99$55.99→ $44.79
- 2 certificates verified at the lab10mg$68.00$47.00→ $42.30
- 1 certificate verified at the lab10mg$84.99$64.99→ $55.24
Fast FedEx shipping · Discreet packaging
Technical Specifications
| Components | CJC-1295 (GHRH analogue) + Ipamorelin (GHSR agonist) |
| Blend Ratio | 1:1 (equal parts CJC-1295 and Ipamorelin) |
| Regulatory Status | Research chemicals; no clinical approval |
| Available Sizes | 5mg (2.5mg each), 10mg (5mg each) |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Source CJC-1295 / Ipamorelin Blend at Purgo Labs
10mg $55.99 list · $44.79 with code HEALTH · lab-verifiable COA per lot
Other Compounds in This Guide
Related Research Guides
Supporting Research
CJC-1295/Ipamorelin blend is a commonly used research combination. No clinical trials have been conducted on this specific blend. Individual constituent evidence: CJC-1295 has limited human PK/PD data; ipamorelin evidence is preclinical only.
References
- Teichman SL, et al.HUMAN PK/PD — CJC-1295 constituentCJC-1295 pharmacokinetic and GH-releasing data in humans; limited to PK/PD, not efficacy for body composition or anti-aging claims.
- Raun K, et al.PRECLINICAL — ipamorelin constituentEuropean Journal of Endocrinology. 1998. PubMedIpamorelin characterization as selective GH secretagogue in preclinical models; does not establish blend efficacy.
Research Databases
Ready to Source CJC-1295 / Ipamorelin Blend?
Purgo Labs offers CJC-1295 / Ipamorelin Blend with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.